LUCD - NASDAQ
Lucid Diagnostics Inc.
$1.02
+0.49%Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
At a Glance
Live Snapshotlucd
Total Liabilities and Equity
Last Annual Value
40.45M
3-Year CAGR
8%
5-Year CAGR
79%
10-Year CAGR
117%
Lucid Diagnostics Inc. Competitors Analysis of Total Liabilities and Equity
| Company | Total Liabilities and Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Lucid Diagnostics Inc. NASDAQ:LUCD | 40.45M | 14.0% | -7.3% | N/A | |
 Owlet, Inc. NYSE:OWLT | 85.60M | 24.7% | -9.4% | N/A | |
 Rapid Micro Biosystems, Inc. NASDAQ:RPID | 74.85M | -19.5% | -20.9% | N/A | |
 Scilex Holding Company NASDAQ:SCLX | 364.98M | 53.3% | 36.2% | N/A | |
 Metagenomi, Inc. Common Stock NASDAQ:MGX | 221.10M | -15.4% | 9.3% | N/A | |
 Anika Therapeutics, Inc. NASDAQ:ANIK | 190.27M | -11.1% | -11.4% | -2.3% | |
 Solana Company NASDAQ:HSDT | 303.93M | 240.6% | 84.8% | N/A | |
 Insight Molecular Diagnostics Inc. NASDAQ:IMDX | 25.76M | -29.9% | -30.6% | 6.0% | |
 LENSAR, Inc. NASDAQ:LNSR | 71.43M | 0.9% | 1.5% | N/A | |
 TScan Therapeutics, Inc. NASDAQ:TCRX | 228.79M | -5.6% | 4.0% | N/A | |
 AVITA Medical, Inc. NASDAQ:RCEL | 56.39M | -20.4% | -13.4% | 22.1% |
Lucid Diagnostics Inc. Fair Value Envelope
Related Guides
Continue your LUCD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.